All In MedTech

FDA Clearance Tracker · P950027-S009

HYALGAN

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 1, 2008 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 1, 2008

Approved

Time to decision

316 days

Received Jun 20, 2007. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P950027-S009
Device name
HYALGAN
Applicant location
Abano Terme
Received
Jun 20, 2007
Decided
May 1, 2008
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P950027

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MODIFICATION OF THE MANUFACTURING PROCESS FOR HYALGAN FOR PRODUCING HYALURONATE BY A BACTERIAL FERMENTATION AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NONPHARMACOLOGIC THERAPY, AND TO SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.

Source documents

Other decisions for Fidia Farmaceutici S.P.A.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.